CliffBio
small molecule

SERNIVO

BETAMETHASONE DIPROPIONATE

Loss of exclusivityAugust 2030latest FDA-listed patent expiry
CompanyPrimus Pharmaceuticals →View the full company profile on CliffBio

Drug detail

Brand nameSERNIVO
Active ingredientBETAMETHASONE DIPROPIONATE
StrengthEQ 0.05% BASE/SPRAY
Dosage formSPRAY
RouteTOPICAL
ModalitySmall molecule
FDA approvalFebruary 2016
Marketing statusRX

Listed patents

PatentExpiresType
9775851August 2030product
9364485August 2030product
9655907August 2030product
10179137August 2030product
9433630August 2030product
9877974August 2030product
9439911August 2030product

More from Primus Pharmaceuticals

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

SERNIVO patent cliff — loss of exclusivity August 2030 | CliffBio